US FDA blesses Novartis Cushing's disease drug Signifor
This article was originally published in Scrip
Executive Summary
The US FDA granted approval to Novartis's Signifor (pasireotide) as a treatment for adults with Cushing's disease for whom pituitary surgery is not an option or has not been curative.